29.03.2021 duration: 3 min

ADCC antibody – The benefits of ADCC enhanced antibodies

An ADCC antibody is an artificially cultivated monoclonal antibody engineered to exhibit a decreased fucose content that in turn leads to higher ADCC. ADCC stands for antibody-dependent cellular cytotoxicity.

The popularity of ADCC enhanced antibodies is consistently growing. Since any type of genetically modified and cultivable antibody is of interest for players in the biopharmaceutical and life-science industries. 

Thanks to a number of beneficial properties, they can be used in a number of medications and treatments targeting autoimmune diseases, cancer and viral diseases such as COVID-19. The two major benefits are:

  • remarkable specificity or
  • unique binding properties

In the particular case of ADCC (antibody-dependent cellular cytotoxicity) enhanced antibodies, those binding properties are further amplified, resulting in an elevated killing activity against tumorigenic and infected cells. 

What is an ADCC enhanced antibody?

But what exactly are ADCC enhanced antibodies? The therapeutic antibodies show a higher antibody-dependent cellular cytotoxicity for the reason of decreased fucose content via afucosylation. Therefore, they are also known as afucosylated antibodies.

ADCC forms part of the humoral immune response to limit and contain infection and has recently been identified as one of the critical mechanisms underlying the clinical efficacy of therapeutic antibodies, especially anticancer antibodies.

Therapeutic antibodies fully lacking the core fucose of the Fc oligosaccharides have been found to exhibit much higher ADCC in humans than their fucosylated counterparts.

3 benefits of ADCC antibodies

ADCC enhancement technology is expected to play a key role in the development of therapeutic antibodies with improved clinical efficacy. A number of preclinical and clinical trials regarding the application of non-fucosylated antibody therapeutics are currently underway.

But why are ADCC enhanced antibodies seeing such a steady rise in popularity? Well, they exhibit a number of significant benefits, the three major ones being:

  • enhanced ADCC activity 
  • improved FcγIIIa binding properties – 
  • quick and easy cultivation with a profitable yield

ADCC antibodies against viruses

As several studies have shown, enhancing the potency of ADCC could be an effective way of combating influenza virus infection. But it doesn’t stop here: ADCC may be effective in controlling other viral infections – like the Corona virus currently causing so much havoc – too.

ADCC has been shown to provide cross-strain protection and to assist in viral clearance, making it an attractive target for “universal” vaccine designs. ADCC-mediating antibodies also target other proteins on the virus surface, making it a potentially important mechanism for protective immunity in herpes simplex virus infections.

Treatment of cancer with therapeutic antibodies

Researchers are able to design antibodies that specifically target a certain antigen, such as the one found on cancer cells before then multiplying said antibody in the lab. The result are monoclonal antibodies that are used to treat many diseases, including some types of cancer.

ADCC enhancement is important to push the efficacy of cancer antibodies as the artificially decreased fucose content that leads to ADCC also results in an elevated killing activity against tumorigenic and infected cells, making them more powerful and efficient. 

So it is hardly surprising that the popularity of ADCC enhanced antibodies to be utilized in the development of next-generation therapeutic antibodies is constantly growing.

Interested in recombinant antibodies?

    Afucosylated antibodies for ADCC enhancement from evitria

    The constantly growing demand is just one of the reasons why antibody production and design plays a crucial role in todays life-science industry, be it to increase activity as well as functionality, reduce immunogenicity or extend the half-life.

    The scientists at evitria are specializing in afucosylated antibodies for ADCC enhancement. ​One of the most recent additions to the company’s services is the state-of-the-art GlymaxX® technology, licensed from ProBioGen, used for the generation of afucosylated antibodies by means of transient expression in CHO cells.

    evitria holds exclusive GlymaxX® licence

    The company holds an exclusive licensing partnership to offer afucosylation via ProBioGen’s GlymaxX® technology for your transient antibody expression needs. This technology facilitates the expression of both native and afucosylated variants. 

    The technology can be applied to your standard host cell line. Alternatively, we can offer our own optimized GlymaxX host cell line, or even re-engineer existing producer clones. GlymaxX cell lines are stable and compatible with highest titer production processes.

    Previous article The history of antibodies
    Next article Afucosylated antibodies and the difference to recombinant antibodies

      Subscribe to the evitria newsletter and stay up to date